AKIP1 Antibody

What is AKIP1 and what are its key cellular functions?

AKIP1 (A-Kinase Interacting Protein 1) is a small 23 kDa protein that functions as a signaling adaptor molecule with multiple cellular roles. At the molecular level, AKIP1 regulates cAMP-dependent protein kinase signaling and belongs to the cascade of NF-kappa-B activation . AKIP1 has several key functions:

• Acts as a molecular scaffold through interaction with mitochondrial apoptosis-inducing factor (AIF)

• Enhances protein kinase A (PKA) activity in cellular stress responses

• Promotes physiological hypertrophy in cardiomyocytes

• Activates HIF-1α and β-catenin signaling pathways in cancer cells

• Modulates mitochondrial integrity during ischemic stress

AKIP1 demonstrates distinct subcellular localization patterns, being present in both mitochondria and the nucleus, which allows it to coordinate signaling between these cellular compartments .

Which experimental techniques are most effective for studying AKIP1 expression?

Based on published research, multiple complementary techniques have proven effective for AKIP1 detection:

Western Blotting: Optimal for quantitative analysis of AKIP1 protein levels in cell lysates. Typically requires 10-15 μg of total protein per lane for reliable detection . When preparing samples, it's critical to use phosphatase and protease inhibitors as AKIP1 is highly susceptible to proteolytic degradation .

Immunofluorescence: Effective for visualizing subcellular localization of AKIP1. Recommended antibody dilutions range from 0.25-2 μg/mL . Co-staining with compartment markers (e.g., cytochrome C for mitochondria, PARP1 for nucleus) helps confirm AKIP1 localization patterns .

Electron Microscopy: Provides high-resolution visualization of AKIP1 at the ultrastructural level. Particularly useful for detecting AKIP1 clusters in nuclear and mitochondrial compartments .

Immunoprecipitation: Valuable for studying AKIP1 protein-protein interactions, such as those with AIF and Hsp-70 .

How should I optimize immunolabeling protocols for AKIP1 detection in electron microscopy studies?

For optimal AKIP1 detection in electron microscopy studies, the following detailed protocol has proven effective:

• Sample preparation:

  • Fix tissues immediately in 2% glutaraldehyde and 2% paraformaldehyde solution in 0.1 M sodium cacodylate

  • Post-fix in 1% osmiumtetraoxide and 1.5% potassium ferrocyanide

  • Dehydrate and embed in EPON epoxy resin before sectioning (80 nm ultrathin sections)

• Immunolabeling sequence:

  • Etch samples with 1% periodic acid for 10 minutes

  • Block with 1% bovine serum albumin in tris-buffered saline (pH 7.4) for 30 minutes

  • Incubate with primary AKIP1 antibody for 2 hours

  • Wash thoroughly and incubate with biotinylated secondary antibody (goat-anti-rabbit; 1:400 dilution) for 1 hour

  • Incubate with streptavidin-conjugated QD655 (1:1000 dilution) for 1 hour

• Imaging technique:

  • Use scanning and transmission electron microscopy (STEM)

  • Process images into a nanotomy map using external scan generator software

  • For elemental composition analysis of observed structural changes, employ energy-dispersive X-ray (EDX) detection

This approach allows visualization of AKIP1 protein clusters within specific subcellular compartments, particularly valuable for identifying its localization within cardiomyocyte nuclei .

What controls should be included when validating AKIP1 knockdown efficiency?

When validating AKIP1 knockdown efficiency, a comprehensive set of controls is essential:

• RNAi sequence selection:

  • Target exon 2 of AKIP1 (e.g., sequence UCC UCU UGG CCC UCU CCA GCA CUUC) to ensure degradation of all endogenous AKIP1 splicing variants, including AKIP1b and AKIP1c

• Essential controls:

  • Negative control: Non-targeting RNAi with similar GC content

  • Transfection efficiency control: Co-transfection with fluorescent marker

  • Loading control: GAPDH or α-Tubulin for Western blot normalization

• Validation methods (multiple required):

  • Western blot: Quantify protein reduction compared to control (normalized to loading control)

  • qRT-PCR: Confirm mRNA reduction

  • Functional assays: Verify phenotypic changes associated with AKIP1 depletion:

    • For cancer cells: Invasion assays, CD133+ cell proportion measurements, sphere formation assays

    • For cardiac cells: Mitochondrial swelling assays, cytochrome C release measurements

• Rescue experiment: Re-introduce AKIP1 expression to confirm that observed phenotypes are specifically due to AKIP1 depletion rather than off-target effects

How does AKIP1 contribute to cardiac protection during ischemia/reperfusion injury?

AKIP1 serves as a key molecular regulator of cardiac protection during ischemia/reperfusion (I/R) injury through multiple mechanisms:

• Mitochondrial integrity preservation:

  • AKIP1 overexpression decreases mitochondrial swelling and cytochrome C release during I/R injury

  • Reduces reactive oxygen species (ROS) generation in mitochondria under both state 3 and 4 respiration with complex I substrates, as demonstrated by electron paramagnetic resonance (EPR)

• Protein interactions and signaling:

  • Forms a complex with apoptosis-inducing factor (AIF) in mitochondria, potentially sequestering AIF and preventing its translocation to the nucleus during low genotoxic stress

  • Increases mitochondrial PKA activity, resulting in phosphorylation of specific proteins including ATP synthase α-subunit (60 kDa)

• Functional improvements:

  • Hearts with AKIP1 overexpression show significantly improved recovery parameters after I/R injury:

    • Increased developed pressure

    • Decreased diastolic dysfunction

    • Enhanced inotropic state (force of muscle contraction)

    • Improved lusitropic state (myocardial relaxation)

    • Reduced lactate dehydrogenase (LDH) release throughout reperfusion

• Early response mechanism:

  • AKIP1 serves as an early-response protein triggered by oxidative stress

  • Upregulated after short durations of ischemia and reperfusion

  • Induction might be related to microRNA regulation or proteolytic degradation pathways

The protective effects appear to be particularly important in interfibrillar mitochondria (IFM), where AKIP1 is more abundant compared to subsarcolemmal mitochondria (SSM) .

What molecular pathways does AKIP1 regulate during exercise-induced cardiac hypertrophy?

AKIP1 promotes physiological cardiomyocyte hypertrophy through regulation of several distinct molecular pathways:

• RSK3-PP2Ac-SRF pathway:

  • AKIP1 overexpression reduces p90 ribosomal S6 kinase 3 (RSK3) levels

  • Increases phosphatase 2A catalytic subunit (PP2Ac) expression

  • Promotes dephosphorylation of serum response factor (SRF)

  • These changes are associated with increased cardiomyocyte length rather than width, driving the distinctive elongation pattern observed in physiological hypertrophy

• Akt-C/EBPβ-CITED4 pathway:

  • AKIP1 promotes exercise-induced activation of protein kinase B (Akt)

  • Downregulates CCAAT Enhancer Binding Protein Beta (C/EBPβ)

  • De-represses Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4 (CITED4)

  • This signaling cascade contributes to the physiological hypertrophic response

• Nuclear AKIP1 clusters:

  • Electron microscopy has detected clusters of AKIP1 protein in cardiomyocyte nuclei

  • These clusters potentially influence signalosome formation and predispose a switch in transcription upon exercise

  • May serve as nodal points for physiological reprogramming of cardiac remodeling

These findings suggest AKIP1 functions as a central coordinator that distinguishes physiological from pathological cardiac hypertrophy through activation of specific signaling cascades.

How does AKIP1 influence cancer cell invasion and stemness under hypoxic conditions?

AKIP1 plays a critical regulatory role in promoting both cancer cell invasion and stemness properties under hypoxic conditions, particularly in gastric cancer:

• Cellular responses to hypoxia:

  • Hypoxia enhances invasive cell count, CD133+ cell proportion, and sphere formation in gastric cancer cell lines (AGS and MKN45)

  • AKIP1 expression is significantly elevated under hypoxic conditions

• Invasion mechanism:

  • AKIP1 knockdown inhibits cell invasion under hypoxia

  • This effect operates through modulation of HIF-1α, VEGF, β-catenin, and CBP expression

  • AKIP1 overexpression produces the opposite effect, enhancing invasion

• Stemness regulation:

  • AKIP1 influences cancer stemness markers:

    • Regulates CD133+ cell proportion

    • Modulates sphere formation capacity

  • Knockdown of AKIP1 significantly reduces these stemness properties

• Signaling pathway integration:

  • AKIP1 activates both HIF-1α and β-catenin signaling pathways

  • Rescue experiments demonstrate that both HIF-1α and β-catenin overexpression:

    • Promote cell invasion and stemness

    • Attenuate the inhibitory effects of AKIP1 knockdown

These findings indicate AKIP1 functions as a central regulator that coordinates hypoxia response, invasion capacity, and stemness properties in gastric cancer cells through parallel activation of HIF-1α and β-catenin pathways.

What is the relationship between AKIP1 and NF-κB signaling in cancer progression?

AKIP1 functions as a critical modulator of NF-κB signaling in cancer progression through precise regulation of PKA-dependent pathways:

• Molecular mechanism:

  • AKIP1 enhances NF-κB activation by promoting PKA-dependent p65 phosphorylation at Ser-276

  • Specifically, AKIP1 reverses the inhibitory function of PKAc in antagonizing the NF-κB cascade

• Signaling dynamics:

  • Under normal conditions, p65 phosphorylation is induced by either cAMP analogs (Bt2cAMP) or TNFα

  • When cells are treated with both TNFα and Bt2cAMP, p65 phosphorylation and p65-PKAc interaction are typically diminished

  • AKIP1 overexpression reverses this inhibition, significantly increasing p65-PKAc interaction when both Bt2cAMP and TNFα are present

• Experimental evidence:

  • IP-WB assays demonstrate that AKIP1 enhances the binding between p65 and PKAc

  • This enhanced binding correlates with increased phosphorylation of p65 at Ser-276

  • The effects were observed in multiple cell lines including 293, HeLa, MCF7, and MDA-MB231

• Cancer relevance:

  • AKIP1 is upregulated in several cancers

  • Its expression correlates with deteriorative tumor features and poorer survival profiles

  • In gastric cancer specifically, AKIP1 modulates Slug-induced epithelial-mesenchymal transition, enhancing growth and metastasis

This regulatory mechanism provides insight into how AKIP1 contributes to cancer progression by fine-tuning the interplay between PKA signaling and NF-κB activation, potentially offering a novel therapeutic target.

What are common challenges in AKIP1 protein detection and how can they be overcome?

Researchers frequently encounter several challenges when detecting AKIP1 protein. Here are the most common issues and their solutions:

• Proteolytic degradation:

  • Problem: AKIP1 is highly susceptible to proteolytic degradation, even in the presence of standard protease inhibitors

  • Solution:

    • Use enhanced protease inhibitor cocktails containing multiple classes of inhibitors

    • Process samples rapidly at 4°C

    • Consider adding specific calpain and cathepsin inhibitors

    • Avoid repeated freeze-thaw cycles of samples

• Low endogenous expression:

  • Problem: Extremely low AKIP1 protein expression in many cultured cell lines (HeLa, MDA-MB231, HEK 293) despite detectable mRNA

  • Solution:

    • Use enrichment techniques such as immunoprecipitation before Western blotting

    • Employ more sensitive detection methods (e.g., chemiluminescence substrate with extended exposure)

    • Consider using cancer cell lines with known higher AKIP1 expression

    • Analyze subcellular fractions separately to concentrate AKIP1 from specific compartments

• Subcellular localization variability:

  • Problem: AKIP1 localizes to both nucleus and mitochondria, complicating interpretation of results

  • Solution:

    • Always perform subcellular fractionation with appropriate markers (e.g., p84 for nuclear contamination, Calreticulin for ER contamination)

    • Use multiple rounds of purification for mitochondrial preparations

    • Include co-staining with compartment-specific markers in immunofluorescence studies

• Antibody specificity:

  • Problem: Potential cross-reactivity with AKIP1 isoforms or related proteins

  • Solution:

    • Validate antibodies using multiple methods (Western blot, IF, IP)

    • Include positive controls (overexpression systems) and negative controls (AKIP1 knockdown samples)

    • Consider using antibodies targeting different epitopes to confirm results

How can researchers effectively study AKIP1 protein-protein interactions?

Studying AKIP1 protein-protein interactions requires careful methodological considerations:

• Immunoprecipitation-Western Blotting (IP-WB):

  • Optimization strategy:

    • For studying interactions with PKA: Pre-treat cells with cAMP analogue (Bt2cAMP, 3 mM) for 12 hours before lysis

    • For NF-κB pathway interactions: Add TNFα (1 ng/ml) for 6 hours after cAMP treatment

    • Use protein A-Sepharose beads for antibody capture

    • Include appropriate controls (IgG, input lysate)

  • Protein stability consideration: Since endogenous AKIP1 is highly susceptible to proteolytic degradation, overexpression systems may provide more reliable results for interaction studies

• GST pull-down assays:

  • Implementation:

    • Express GST-tagged AKIP1 isoforms in bacterial or mammalian expression systems

    • Use purified GST-AKIP1 for pull-down experiments with cell lysates

    • Identify unique bands by SDS-PAGE and analyze using mass spectrometry

  • Success story: This approach successfully identified AIF and Hsp-70 as AKIP1-interacting proteins

• Mass spectrometry analysis:

  • Workflow:

    • Perform nanoliquid chromatography tandem MS on unique bands from pull-down experiments

    • Confirm interactions by Western blot analysis using specific antibodies

  • Validation approach: For interactions identified by MS, confirm with reverse co-IP where possible

• Isoform-specific considerations:

  • Different AKIP1 isoforms show distinct interaction patterns

  • AKIP1a (present in both humans and rodents) primarily interacts with AIF

  • All three AKIP1 isoforms interact with Hsp-70

  • When studying interactions across species, note that mouse and human AKIP1a share only 70% homology

This multi-method approach provides complementary data that strengthens confidence in identified protein-protein interactions involving AKIP1.

How is AKIP1 being investigated as a potential therapeutic target in cardiac and cancer research?

AKIP1 is emerging as a promising therapeutic target in both cardiac protection and cancer treatment paradigms:

• Cardiac protection applications:

  • Therapeutic rationale: AKIP1 overexpression protects against ischemia/reperfusion injury through:

    • Enhanced mitochondrial integrity maintenance

    • Reduced ROS generation

    • Improved functional recovery parameters

  • Delivery approaches under investigation:

    • Adenoviral gene therapy using tetracycline-off regulated systems

    • Intracoronary gene transfer methods have demonstrated efficacy in animal models

  • Future directions: AKIP1 targeted specifically to mitochondria may provide enhanced protection against age-related cardiovascular decline, as aged hearts show reduced interfibrillar mitochondria (where AKIP1 is most abundant)

• Cancer treatment implications:

  • Dual targeting potential:

    • In hypoxic tumors: AKIP1 inhibition could reduce invasion and stemness properties by suppressing HIF-1α and β-catenin pathways

    • In NF-κB driven cancers: Disrupting AKIP1-PKA-p65 interactions might reduce cancer progression

  • Biomarker potential: AKIP1 upregulation correlates with deteriorative tumor features and poorer survival in multiple cancers

• Integration with existing therapies:

  • For cardiac applications: AKIP1 induction might mimic ischemic preconditioning without the risks of actual ischemia

  • For cancer applications: AKIP1 targeting could potentially sensitize hypoxic tumor regions to conventional therapies by reducing stemness properties

These emerging therapeutic directions highlight AKIP1's position at the intersection of energy metabolism, stress response, and cell survival pathways across multiple disease contexts.

What recent technical advances have improved our ability to study AKIP1 function?

Recent technical innovations have significantly enhanced our capacity to investigate AKIP1's complex biological functions:

• Advanced imaging technologies:

  • Large-scale electron microscopy (nanotomy):

    • Allows visualization of AKIP1 at nano-anatomical resolution

    • Enables mapping of AKIP1 protein clusters within specific subcellular compartments

    • Integration with EDX detection provides elemental composition analysis

  • Correlative light and electron microscopy:

    • Combines immunofluorescence data with ultrastructural context

    • Particularly valuable for studying AKIP1's dual localization in nucleus and mitochondria

• Mitochondrial functional assays:

  • Electron paramagnetic resonance (EPR):

    • Enables precise measurement of ROS generation in isolated mitochondria

    • Has demonstrated decreased ROS production in AKIP1-overexpressing hearts

  • Calcium swelling assays:

    • Quantifies mitochondrial permeability transition pore opening

    • Shows reduced swelling in mitochondria from AKIP1-overexpressing tissue

• Protein interaction mapping:

  • Quantitative mass spectrometry:

    • Identifies AKIP1-interacting proteins (AIF, Hsp-70)

    • Enables detection of post-translational modifications in interacting partners

  • Phosphoproteomic analysis:

    • Reveals AKIP1-dependent phosphorylation events

    • Identified ATP synthase α-subunit as a potential downstream target

• In vivo models with conditional expression:

  • Cardiomyocyte-specific AKIP1 transgenic mice:

    • Allow evaluation of AKIP1 overexpression effects in intact animals

    • Enable assessment of exercise-induced cardiac hypertrophy mechanisms

  • Tetracycline-regulated expression systems:

    • Provide temporal control of AKIP1 expression

    • Facilitate investigation of acute vs. chronic effects

These methodological advances have collectively deepened our understanding of AKIP1's multifaceted roles in cellular signaling, stress response, and disease contexts.

AKIP1 Detection Methods Comparison Table

AKIP1 Physiological Effects in Different Experimental Models